IDH1 and IDH2 mutations in gliomas

New England Journal of Medicine

Volumn 360, Issue 8, 2009, Pages 765-773

  Yan, Hai ^a,f   Parsons, D Williams ^b,d   Jin, Genglin ^a   McLendon, Roger ^a   Rasheed, B Ahmed ^a   Yuan, Weishi ^e   Kos, Ivan ^a   Batinic Haberle, Ines ^a   Jones, Siân ^b   Riggins, Gregory J ^c   Friedman, Henry ^a   Friedman, Allan ^a   Reardon, David ^a   Herndon, James ^a   Kinzler, Kenneth W ^b   Velculescu, Victor E ^b   Vogelstein, Bert ^b   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CELL CULTURE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC TRAIT; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MALE; OLIGODENDROGLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOMATIC MUTATION; WILD TYPE; WORLD HEALTH ORGANIZATION;

EID: 60849115270     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0808710     Document Type: Article

References (23)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumours of the central nervous system. 4th ed. Lyon, France: IARC Press, 2007.
2. Burger PC, Scheithauer BW, Paulus W, et al. Pilocytic astrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press, 2000:45-51.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507. [Erratum, N Engl J Med 2008;359:877.]
5. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64: 6892-9.
6. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblas-toma. Am J Pathol 2007;170:1445-53.
7. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455: 1061-8.
8. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
9. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342:705-8.
10. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-3.
11. Wong AJ, Bigner SH, Bigner DD, Kin-zler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987; 84:6899-903.
12. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89:2965-9.
13. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
14. Weber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Onco-gene 1996;13:983-94.
15. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oli-godendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-86.
16. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glio-blastoma multiforme. Science 2008;321: 1807-12.
17. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
18. Wang TL, Diaz LA Jr, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004;101:3089-94.
19. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145: 1175-90.
20. Batinic-Haberle I, Benov LT. An SOD mimic protects NADP+-dependent isoci-trate dehydrogenase against oxidative in-activation. Free Radic Res 2008;42:618-24.
21. Xu X, Zhao J, Xu Z, et al. Structures of human cytosolic NADP-dependent isoci-trate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 2004;279:33946-57.
22. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68:8673-7.
23. Jennings GT, Minard KI, McAlister-Henn L. Expression and mutagenesis of mammalian cytosolic NADP+-specific iso-citrate dehydrogenase. Biochemistry 1997; 36:13743-7.